Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population

Aim: Currently, atezolizumab combined with bevacizumab is the standard first-line treatment for unresectable hepatocellular carcinoma (HCC), but lenvatinib or sorafenib are still recommended for these patients for some reasons. The aim of the study was to determine the outcomes of Taiwanese patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Shou-Wu, Yang, Sheng-Shun, Lien, Han-Chung, Peng, Yen-Chun, Ko, Chung-Wang, Lee, Teng-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911194/
https://www.ncbi.nlm.nih.gov/pubmed/35268535
http://dx.doi.org/10.3390/jcm11051444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911194/
https://www.ncbi.nlm.nih.gov/pubmed/35268535
http://dx.doi.org/10.3390/jcm11051444

Ejemplares similares